PT-141, the peptide bremelanotide, reaches the body by injection rather than by mouth, because as a cyclic heptapeptide it is broken down in the gastrointestinal tract. The only approved form is a fixed 1.75 mg subcutaneous dose in a single-use, pre-filled autoinjector, cleared for acquired, generalized hypoactive sexual desire disorder in premenopausal women and used on demand rather than daily. The same peptide also circulates as gray-market research-grade powder that carries none of the fixed dose, sterility controls, or frequency limits the labeled product was built around.
The only FDA-approved form of PT-141 is a fixed 1.75 mg subcutaneous dose in a single-use autoinjector, taken on demand at least 45 minutes before activity and capped at one dose per 24 hours and eight per month.
The approved presentation delivers one fixed strength, 1.75 mg per dose, with no lower or higher labeled options and no titration schedule, so every patient in the indication receives the same amount. That fixed choice reflects the on-demand nature of the condition and the trial design behind approval, where 1.75 mg was the strength studied for efficacy and tolerability in premenopausal women.
The approved product delivers a single fixed strength of 1.75 mg of bremelanotide in 0.3 mL, about 5.83 mg/mL, from a metered single-use autoinjector that cannot be dose-adjusted.
On-demand delivery means the device is used only when activity is anticipated, not on a fixed daily or weekly calendar, which is why the autoinjector is engineered for a single self-contained actuation with minimal preparation. The published handling sequence is short and ends in disposal, since no part of the dose is held back for a later occasion.
The autoinjector is a single self-contained actuation, inspected through its window, pressed to cleaned abdominal or thigh skin until the full 0.3 mL is expelled, then discarded whole into a sharps container.
The labeling sets a floor of at least 45 minutes before anticipated activity, with the exact timing left to how the individual patient responds within that window. That floor tracks the drug's pharmacokinetics rather than any fixed clock: plasma levels rise over the first hour and peak around an hour after a subcutaneous dose.
The labeling directs a dose at least 45 minutes before anticipated activity, a floor set by the drug's pharmacokinetics, since plasma concentrations peak about one hour after subcutaneous injection.
Two hard ceilings govern how often the approved product may be used, and both are framed as frequency limits rather than a daily-dosing allowance because the indication is episodic. The drug is documented as meant for use ahead of anticipated activity, not accumulated on a routine schedule.
| Limit | Boundary | What it holds in check |
|---|---|---|
| Per 24 hours | No more than one 1.75 mg dose | Stacking a second dose before the first has cleared |
| Per month | No more than eight doses | Cumulative exposure and its side-effect load |
The labeled regimen permits no more than one 1.75 mg dose in any 24-hour period and no more than eight doses in any single month.
The approved injection is documented into the abdomen or the front of the thigh, the two sites named for the autoinjector, both offering accessible subcutaneous fat for self-administration. The published technique centers on protecting the tissue across repeated use rather than on any single injection.
The approved subcutaneous dose is documented into the abdomen or front of the thigh, with site rotation and pre-injection skin cleaning cited to reduce local irritation and lipohypertrophy.
Outside the approved product, PT-141 is sold as a lyophilized powder in a sealed vial, most often labeled for research use only, and the dose is not metered but back-calculated by the user. Every step in this pathway rests on the user's own math, measurement, and sterile handling, which is the sharp break from the labeled autoinjector.
In the gray-market pathway the dose is not metered but back-calculated from vial size and diluent volume, so a 10 mg vial reconstituted in 2 mL of bacteriostatic water yields 5 mg/mL, leaving accuracy, sterility, and purity entirely on the user.
Before the subcutaneous autoinjector, bremelanotide was investigated as an intranasal spray, which is a large part of why PT-141 is still discussed in some circles as a nasal product even though the approved form is an injection. The subcutaneous route was carried forward largely because the intranasal program raised blood-pressure concerns that were harder to control with nasal absorption.
| Criteria | Intranasal (historical) | Subcutaneous (approved) |
|---|---|---|
| Absorption | Across nasal mucosa, faster to begin | Under the skin, peaks around one hour |
| Dose consistency | More variable with technique and mucosa | More predictable and reproducible |
| Blood-pressure signal | More pronounced or less controllable | Weighed as the more manageable option |
| Outcome | Not carried to approval | The marketed autoinjector |
Bremelanotide's intranasal spray was dropped in favor of the subcutaneous autoinjector largely because nasal absorption gave more variable dosing and a more pronounced blood-pressure signal.
Exceeding the frequency limits is documented to push the drug's known adverse effects from tolerable and transient toward more pronounced and, with repetition, more lasting. The two ceilings each guard against a different harm, so overshooting either one moves exposure past the bounds studied at approval.
Exceeding one dose per 24 hours amplifies the acute cardiovascular effects, while passing eight doses per month raises the risk of focal hyperpigmentation on the face, gums, and breasts through melanocortin-receptor action.
This storage question applies mainly to the reconstituted-powder pathway, since the approved autoinjector is single-use and discarded immediately rather than held between doses. Once a dry vial is reconstituted, the solution becomes a stability and contamination judgment call that the sealed product never imposes.
A reconstituted PT-141 vial is generally refrigerated at 2 to 8 degrees Celsius, protected from light, and treated as usable for a matter of weeks, whereas the sealed single-use autoinjector is never held as a partially used reservoir.
Educational use only. This article describes what the published scientific and clinical literature reports about PT-141 (bremelanotide). It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
